Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease
Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease
复制标题
DOI：
10.1016/j.expneurol.2003.08.008
复制
发表时间：
2003-11-01
影响因子：
5.3
通讯作者：
Stoessl, AJ
中科院分区：
文献类型：
--
作者：
Brooks, DJ;Frey, KA;Stoessl, AJ
帕金森病（PD）研究的一个主要目标是开发治疗方法来减缓黑质纹状体多巴胺能系统的进行性退化并减少患者的功能衰退。由于一旦多巴胺能治疗开始，临床评估反映黑质纹状体多巴胺能系统状态的能力存在不确定性，PD研究人员一直在寻求开发疾病的替代测量方法。一种已被广泛探索的方法是使用放射性示踪剂进行神经成像，该放射性示踪剂与黑质纹状体多巴胺能轴突中多巴胺能神经传递的核心过程相互作用——通过芳香族氨基酸脱羧酶 (AADC) 将左旋多巴转化为多巴胺，[F-18]氟多巴 PET，通过囊泡单胺转运蛋白 2 将多巴胺储存在突触囊泡中(VMAT2)、(+)-[C-11]二氢丁苯那嗪 PET，以及通过多巴胺转运蛋白 (DAT) 将多巴胺重新摄取到轴突中、[I-123]beta-CIT SPECT 以及许多其他 PET 和 SPECT 配体。在美国神经病学学会第 54 届年会上，活跃在生物制造、神经成像和神经保护领域的一组研究人员聚在一起回顾了上述三种技术。会议之前，与会者就神经影像技术的 10 项标准达成了共识，该技术被认为足以作为 PD 进展的生物标志物，以及每种技术的可用数据表明满足该标准的水平。对上述标准和三种成像技术进行了审查，并介绍了该会议的结果。 (C) 2003 Elsevier Inc. 保留所有权利。
A major goal of research in Parkinson's disease (PD) has been the development of treatments to slow the progressive degeneration of the nigrostriatal dopaminergic system and to reduce the functional decline of patients. Because of the uncertainty in the ability of the clinical evaluation to reflect the status of the nigrostriatal dopaminergic system once dopaminergic therapy has commenced, investigators in PD have sought to develop alternative measures of disease. One approach, which has been extensively explored, is neuroimaging with radiotracers that interact with processes central to dopaminergic neurotransmission in the nigrostriatal dopaminergic axons-conversion of levodopa to dopamine through aromatic amino acid decarboxylase (AADC), [F-18]fluorodopa PET, storage of dopamine in synaptic vesicles via the vesicular monoamine transporter 2 (VMAT2), (+)-[C-11]dihydrotetrabenazine PET, and reuptake of dopamine into axons via the dopamine transporter (DAT), [I-123]beta-CIT SPECT, and a number of other PET and SPECT ligands. During the 54(th) Annual Meeting of the American Academy of Neurology, a group of investigators active in the fields of biomakers, neuroirnaging, and neuroprotection met to review the three techniques mentioned above. Prior to the meeting, the participants developed consensus on a set of 10 criteria for a neuroimaging technique to be considered adequate as a biomarker for progression of PD and levels at which the available data for each technique indicate that the criterion was met. The criteria and each of the three imaging techniques mentioned above were reviewed, and the results of that meeting are presented. (C) 2003 Elsevier Inc. All rights reserved.